Shake-up coming for Top 10 drugs

Posted 25 July 2023 AM

MSD's Keytruda is tipped to become the top-selling pharma product for 2023, and to keep that crown for at least five years.

According to an analysis by Boston Consulting Group of data from Evaluate Pharma, Keytruda will bring in AU$35.7 billion in global sales this year, and increase that to $47.5 billion by 2028. If that trend plays out in Australia, it would see pre-rebate R/PBS reimbursements for the monoclonal antibody increase to around $586 million, compared to $440 million in 2022.

To see the whole article, please login